The groundbreaking approach of this peptide represents a major breakthrough in the care of type 2 diabetes. Unlike existing medications, tirzepatide targets dual pathways – glucagon-like peptide-1 (GLP-1) and GIP – https://tirzepatide-peptide016902.activosblog.com/40543930/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment